Gold compounds in rheumatoid arthritis: clinical-pharmacokinetic correlates.
Currently available techniques do not enable the clinician to identify which patients with rheumatoid arthritis will respond favorably to chrysotherapy or to predict which patients will develop gold-related complications. Gold concentrations are similar in blood, urine, feces, skin, hair and nails in gold-responders and non-responders, and in gold-toxic and non-toxic patients. However, gold toxicity is a function of dosage schedule; higher than conventional doses increase the prevalence and severity of adverse reactions. Preliminary observations suggest that the frequency of common side-effects (e.g. dermatitis, stomatitis, proteinuria) from oral gold (auranofin) is less than that incurred with intramuscular gold prepartions. The possible genetic predisposition to develop gold toxicity is under investigation.
D000375:Aging; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D006051:Aurothioglucose / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D005243:Feces / Q000032:analysis; D005260:Female; D006046:Gold / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use*; D006052:Gold Sodium Thiomalate / Q000627:therapeutic use; D006801:Humans; D008297:Male; D014556:Urine
D006052:Gold Sodium Thiomalate; D006051:Aurothioglucose; D006046:Gold